Low impact
AstraZeneca announced Breztri is now available in the US as the first fixed-dose triple therapy for asthma patients aged 12 and older.
FirstSquawk07/20, 08:38 PM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.